Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02753686
Title Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Tamoxifen

Exemestane

Fulvestrant

Letrozole

Anastrozole

Everolimus + Exemestane

Age Groups: senior | adult
Covered Countries CAN


No variant requirements are available.